Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 16/20 | 0.73 |
| ▸ | ESR2 | Q92731 | 16/20 | 0.73 |
| ▸ | PSMB1 | P20618 | 2/20 | 0.46 |
| ▸ | PSMB5 | P28074 | 2/20 | 0.46 |
| ▸ | PSMB2 | P49721 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7200191 | 0.91 | ESR2 (0.72) | ESR1ESR2PSMB1PSMB5PSMB2 | |
| SCHEMBL7205864 | 0.85 | ESR1 (0.98) | ESR1ESR2PSMB1PSMB5 | |
| SCHEMBL7201202 | 0.83 | ESR1 (0.75) | ESR1ESR2 | |
| SCHEMBL7204378 | 0.82 | ESR1 (1.00) | ESR1ESR2 | |
| SCHEMBL7199671 | 0.81 | ESR2 (0.98) | ESR1ESR2PSMB1PSMB5PSMB2 | |
| SCHEMBL7203271 | 0.80 | ESR2 (1.00) | ESR1ESR2 | |
| SCHEMBL7199256 | 0.80 | ESR1 (1.00) | ESR1ESR2PSMB1PSMB5PSMB2 | |
| Hydrochloric Acid SCHEMBL5429417 | 0.68 | ESR1 (0.81) | ESR1ESR2 | |
| SCHEMBL7205462 | 0.67 | ESR2 (0.77) | ESR1ESR2 | |
| SCHEMBL7640214 | 0.65 | ESR1 (0.67) | ESR1ESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6599921-B2 | Antiproliferative agents against estrogen-dependent cancer cells dibenzothiopyran, dibenzopyran and phenanthrene derivatives | NANODESIGN, INC. (CA) | 2003-07-29 | — | — | US | disclosed |
| US-20020156077-A1 | Non-steroidal estrogen receptor ligands | PALOMA PHARMACEUTICALS, INC. | 2002-10-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020156077-A1 | Non-steroidal estrogen receptor ligands | ESRRA, ESRRB, ESRRG | ESR1 6/4885ESR2 4/4885PSMB1 1853/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.